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Abstract
Purpose Non-diagnostic results still hinder the routine
use of core biopsy (CB) and fine needle aspiration (FNA)
in the diagnostic process of renal tumours. Furthermore,
substantial interobserver variability has been reported. We
assessed the added value of combining the results of CB
and FNA by five pathologists in the ex vivo diagnosis of
renal mass.
Methods Two ex vivo core biopsies were taken followed
by two FNA passes from extirpated tumours. All samples
were evaluated by five blinded pathologists. A consensus
diagnosis of the surgical specimen was the index for
comparison. For each pathologist, the number of non-
diagnostic (non-conclusive or undetermined biology and
failed biopsies), correct and incorrect scored cases of each
technique was assessed. When a non-diagnostic CB or
FNA had a correct diagnostic counterpart, this was con-
sidered as of added value.
Results Of the 57 assessed tumours, 53 were malignant.
CB was non-diagnostic in 4–10 cases (7–17.5%). FNA
established the correct diagnosis in 1–7 of these cases.
FNA was non-diagnostic in 2–6 cases (3.5–10.5%), and the
counterpart CB established the correct diagnosis in 1–6 of
these cases.
For the 5 pathologists, accuracy of CB and FNA varied
between 82.5–93% and 89.5–96.5%, respectively. Combi-
nation of both types of biopsy resulted in 55–57 correct
results (accuracy 96.5–100%), i.e., an increase in accuracy
of 3.5–14%.
Conclusion Combining the result of CB and FNA in renal
mass biopsy leads to a higher diagnostic accuracy. Rec-
ommendations on which technique used should be adapted
to local expertise and logistic possibilities.
Keywords Renal cell carcinoma  Aspiration biopsy 
Needle biopsy  Kidney neoplasm  Pathology
Introduction
Most renal tumours are incidental findings discovered by
cross-sectional or ultrasound imaging, and these imaging
techniques are also the current pre-operative ‘gold stan-
dard’ to determine the characteristics of the renal tumour.
However, most studies have also shown that differentiating
benign from malignant renal mass based on radiological
features is difficult, and subtype differentiation of renal cell
carcinoma (RCC) is highly uncertain [1].
In contrast to suspected malignancies in other organs,
pre-operative biopsy to confirm the pathology has not been
widely adopted in renal tumours. Fear of potential tract
seeding and low accuracy of the test were the most
important caveats. However, tract seeding has not been
K. Barwari (&)  I. P. Kummerlin  H. Wijkstra 
J. J. De la Rosette  P. Laguna
Department of Urology, AMC University Hospital,
University of Amsterdam, Amsterdam, The Netherlands
e-mail: k.barwari@amc.uva.nl
F. J. ten Kate
Department of Pathology, AMC University Hospital,
Amsterdam, The Netherlands
F. Algaba
Pathology Department, Fundacio´ Puigvert,
Universitat Auto`noma de Barcelona, Barcelona, Spain
I. Trias
Pathology Department, Hospital Plato´, Barcelona, Spain
123
World J Urol (2013) 31:823–827
DOI 10.1007/s00345-011-0703-2
reported since 1994, and the accuracy of renal tumour
biopsy is reaching 90% and higher in some set-ups [1, 2].
Main indications for biopsy in renal masses are clinical T1
masses, suspicion of metastasis from other primary cancer
or infectious disease and before systemic targeted therapy.
The majority of the published studies deal with the
results of core biopsies (CB or Tru-cut biopsies). Fine
needle aspiration (FNA) is less frequently reported,
although some studies show similar accuracy compared
with CB [1]. Survey studies show that if indicated, the
majority of practicing physicians prefers core biopsy (CB)
over FNA. Both techniques have their specific advantages
and disadvantages. Histological core biopsy is thought to
preserve the architecture of the tumour and facilitates the
performance of ancillary tests and immunohistochemistry,
possibly benefitting accuracy. On the other hand, it is more
likely to harvest cells that lead to a diagnosis when mul-
tiple passes are made through the tumour, as is done when
taking an FNA [3–6].
Very few studies have assessed the diagnostic accuracy
of a combination of CB and FNA (e.g. Wood et al. [7]) or
the superiority of one technique over the other. Therefore,
the clinical question remains, when performing a renal
mass biopsy, which technique is the first choice [8]. The
aim of the present study is to asses the accuracy of com-
bining both techniques and the added value of either of the
techniques.
Materials and methods
Fifty-seven consecutively extirpated renal masses were
included in this prospective study. Since no direct inter-
vention was made in these patients, informed consent was
not mandatory.
Immediately after surgery, the fresh specimen was studied
at the pathology laboratory. First one urologist performed
under direct vision two CBs from the periphery of the tumour
with an automatic 18-gauge core biopsy system (Boston
Scientific). The CBs were fixed in formalin, paraffin
embedded and haematoxylin-and-eosin (HE)-stained. Sub-
sequently, the same urologist performed fine needle aspira-
tions of the tumour using a 22-gauge needle. After each of
two passes, two smears were stained for Giemsa and two for
Papanicolaou. After FNAs and CBs were performed, the
surgical specimen was processed according to the guidelines
of the Uropathology Working Group (European Society of
Pathology) [9] and the European Working Group of Uropa-
thology of the European Association of Urology.
All samples were evaluated by five pathologists blinded
for the definitive diagnosis and in an independent manner.
The pathologists classified the biopsies and smears
according to the latest WHO criteria. Samples containing
only normal kidney parenchyma, blood, necrotic tissue or
insufficient tumour tissue to make a definitive diagnosis
(according to the individual pathologist’s assessment) were
classified as non-diagnostic. Samples in which the pathol-
ogist could not decide between malignant or benign were
classified as non-conclusive. Because no diagnosis could
be made in these samples, for the purposes of this article,
they will also be considered non-diagnostic.
After the blind evaluation of the FNAs and CBs was
completed, the five pathologists reached consensus on the
surgical specimen at the multi-head microscope. The
specimen diagnosis was considered the standard reference
to assess the diagnostic accuracy of each of the techniques
and the combination of both. Three of the pathologists
worked in an academic reference centre and two in com-
munity hospitals. All pathologists had experience with
uropathology, renal CBs and general cytology.
The standard reference and the results of the CB and
FNA were classified as malignant, benign or a non-diag-
nostic result. Results were considered accurate when it was
diagnostic and the diagnosis corresponded with the result
of the standard reference in terms of a benign or malignant
mass. Subsequently, we considered the two biopsy tech-
niques together as (one single) index test. A case with one
or both outcomes malignant was considered as a positive
index test, consequently a case with both outcomes being
benign and/or non-diagnostic was considered as a negative
index test (see Table 1).
We analysed the number of correct outcomes of the
index test, i.e., a positive index test with a positive refer-
ence standard or a negative index test with a negative
reference standard outcome.
Results
Patient data are presented in Table 2. Of the 57 renal
masses, four tumours (7.0%) were benign and 53 (93.0%)
were malignant.
For the different pathologists, CB was incorrect or non-
diagnostic in 6–11 cases (10,5–19,3%) with FNA leading
to the correct diagnosis in 0–10 of these cases (0–17,5%).
Table 1 Construction of the index test (CB ? FNA)







M Malignancy, B Benign tumour, ND Non-diagnostic result
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FNA was incorrect or non-diagnostic in 4–16 cases
(7,0–28,1%) with CB leading to the correct diagnosis in
2–10 of these cases (3,5–17,5%) (see Fig. 1).
Results per pathologist
Pathologist 1 had 10 (17,5%) non-diagnostic CBs and 6
(10,5%) non-diagnostic FNAs.
CB was concordant with the reference standard in 47
cases (82,5%), FNA in 46 cases (80,7%). When combining
CB and FNA, there was concordance in 54 cases leading to
an accuracy of the combined biopsy of 94,7%.
Pathologist 2 had 6 (10,5%) non-diagnostic CBs and 3
(5,3%) non-diagnostic FNAs.
CB was concordant with the reference standard in 51
cases (89,5%), FNA in 51 cases (89,5%). When combining
CB and FNA, there was concordance in 56 cases leading to
an accuracy of the combined biopsy of 98,2%.
Pathologist 3 had 4 (7%) non-diagnostic CBs and 3
(5,3%) non-diagnostic FNAs. There were 2 cases with a
non-diagnostic result for both CB and FNA (reference
standard: clear cell RCC and chromophobe RCC, respec-
tively). CB was concordant with the reference standard in
51 cases (89,5%), FNA in 41 cases (71,9%). When com-
bining CB and FNA, there was concordance in 51 cases
leading to an accuracy of the combined biopsy of 89,5%.
Pathologist 4 had 8 (14,1%) non-diagnostic CBs and 2
(3,5%) non-diagnostic FNAs.
CB was concordant with the reference standard in 46
cases (80,7%), FNA in 53 cases (93,0%). When combining
CB and FNA, there was concordance in 56 cases leading to
an accuracy of the combined biopsy of 98,2%.
Pathologist 5 had 8 (14,1%) non-diagnostic CBs and 3
(5,3%) non-diagnostic FNAs. There was 1 case with a non-
diagnostic result for both CB and FNA (reference standard:
chromophobe RCC).
CB was concordant with the reference standard in 49
cases (86,0%), FNA in 53 cases (93,0%). When combining
CB and FNA, there was concordance in 55 cases leading to
an accuracy of the combined biopsy of 96,5%.
In summary, the accuracy of CB to detect a malignant
tumour ranged from 80.7 to 89.5% for the different
pathologists and the accuracy of FNA ranged from 71.9 to
93.0%. When both techniques were combined, the accu-
racy ranged from 89.5 to 98.2% (Table 3).
Discussion
Renal mass biopsy as a diagnostic tool has gained renewed
interest among urologists due to changes in a number of
Table 2 Patient data
Number of tumours 57
Mean age (years) (SD) 61.9 (13.2)







Not known 3 (5.3)
Operation (%)
Radical nephrectomy 39 (68.4)
Partial nephrectomy 18 (31.6)
Pathological diagnosis of surgical specimen (%)
Clear cell RCC 43 (75.4)
Chromophobe RCC 4 (7.0)
Papillary RCC 3 (5.3)
Renal oncocytoma 2 (3.5)
Angiomyolipoma 2 (3.5)
RCC unclassified 1 (1.8)
Urothelial carcinoma 2 (3.5)
SD Standard deviation, RCC Renal cell carcinoma







1 47/57 (82.5) 46/57 (80.7) 54/57 (94.7)
2 51/57 (89.5) 51/57 (89.5) 56/57 (98.2)
3 51/57 (89.5) 41/57 (71.9) 51/57 (89.5)
4 46/57 (80.7) 53/57 (93.0) 56/57 (98.2)
5 49/57 (86.0) 53/57 (93.0) 55/57 (96.5)
Fig. 1 Added value of CB and FNA for every pathologist. Total no.
of tumours is represented by the dashed line (n=57). The first bar for
every pathologist shows the added value of FNA (in green). The
second bar for every pathologist shows the added value of CB (in
blue)
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involved fields. First, the incidence of incidentally dis-
covered SRM increased significantly in the era of widely
accessible imaging modalities and since it is recognised
that these SRMs represent a heterogeneous group of both
benign and malignant pathological conditions with only a
minority bearing high-grade tumours [10] Simultaneously,
advances in surgical management have been made facili-
tating less aggressive treatment modalities for less
aggressive tumours, such as thermal ablation of even active
surveillance [11]. Nowadays pathologists have access to
techniques such as immunohistochemistry and molecular
diagnostics to determine biopsy tissue with higher accuracy
[12].
In previous studies, the accuracy of CB [13, 14] and
FNA has been assessed individually; however, no recom-
mendation to perform the one or the other was given [8].
Since both techniques have different advantages and dis-
advantages, we think one technique can be complementary
to the other.
In this study, we assessed the added value of CB on
FNA and vice versa in determining the biology of a renal
mass by five different pathologists. The consulted pathol-
ogists were practicing at the time of the study in different
hospitals varying from academic centres to community
hospitals, and therefore, we covered a wide clinical spec-
trum and integrated the inter-observer variability which is
demonstrated to be substantial by Ku¨mmerlin et al.
[13, 14].
In our setting, the overall accuracy of CB and FNA is
comparable with figures reported in the recent literature [1,
2] with the accuracy of CB ranging from 80,7 to 89,5%
between the different pathologists and the accuracy of FNA
from 71,9 to 93,0%. However, in this study, no immuno-
histochemistry has been used, which most likely would
have improved the figures.
The second aim of this study was to demonstrate the
superiority of CB over FNA or vice versa. However, we
found comparable accuracy figures for both CB and FNA
(80,7–89,5% for CB and 71,9–93,0% for FNA). Since
accuracy figures of both techniques are approaching each
other, it is hard to proclaim to be either superior or
complementary.
What type of biopsy to perform depends on the local
(logistical) situation. When striving for the highest accu-
racy and minimising the risk of non-diagnostic biopsy
results, it is recommended to use both biopsy techniques.
However, when the given setting has a known high accu-
racy of one of the two techniques, performing this one only
one is recommended in order to save time and resources.
We recognise some limitations of this study. First, the
biopsies were taken in an ex vivo setting. Clinical appli-
cation of biopsies will be an in vivo (percutaneous) setting
presumably leading to lower accuracy figures. However, a
comprehensive recent review comparing accuracy figures
of ex vivo- and clinical biopsy studies showed comparable
if not better results of percutaneous biopsies in a clinical
setting [2], and therefore, a direct extrapolation of the ex
vivo results might be expected. Second, the mean tumour
size in the current study is larger than in SRM in which
biopsy might have major application. However, the mean
tumour size in our series represents the contemporary mean
size at surgery including T1b renal masses, 10% of which
may still be benign [10] justifying biopsy in this range of
tumour size as well. Furthermore, case selection was not
based on clinical premises as the present study was
designed to assess the additional value of either of the
biopsy techniques over a single biopsy. Third, due to the ex
vivo nature of the study, an additional risk of complications
related to the extra biopsies performed cannot be ruled out.
However, large series in the modern literature of CB and
FNA reported very few or no major complications, and
minor complications such as post-biopsy bleeding are very
uncommon and almost never of clinical significance [6, 7,
15, 16].
Lastly, additional biopsy will lead to increased costs in
the clinical setting. In our ex vivo setting, the additional
FNA biopsy would have represented an incremental cost of
247% (core biopsy analysis €85.49 compared with €299.47
for analysing an FNA, including €187.17 for on-site anal-
ysis by a pathology analyst). Ultimately, a proper cost-
benefit analysis including in vivo procedural costs, costs of
complications and cost-benefit in terms of preventing
unnecessary surgical interventions should be carried out
before definitive inclusion of additional biopsies in the
diagnostic algorithm.
Conclusion
Accuracy of CB and FNA is high in this ex vivo setting,
and adding the results of CB to FNA and vice versa
resulted in an accuracy ranging from 89,5 to 98,2% for the
different pathologists. Whether to perform both CB and
FNA depends on the performance of CB and FNA solely
and on the logistical possibilities in the particular setting.
Both techniques should be performed when striving for
minimal non-diagnostic and maximal accurate results.
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